AAAAAA
Results: 1-25/26
Authors:
Bushara, KO
Wheat, JM
Khan, A
Mock, BJ
Turski, PA
Sorenson, J
Brooks, BR
Citation: Ko. Bushara et al., Multiple tactile maps in the human cerebellum, NEUROREPORT, 12(11), 2001, pp. 2483-2486
Authors:
Sanjak, M
Brinkmann, J
Belden, DS
Roelke, K
Waclawik, A
Neville, HE
Ringel, SP
Murphy, JR
Brooks, BR
Citation: M. Sanjak et al., Quantitative assessment of motor fatigue in amyotrophic lateral sclerosis, J NEUR SCI, 191(1-2), 2001, pp. 55-59
Authors:
Speelman, B
Brooks, BR
Post, CB
Citation: B. Speelman et al., Molecular dynamics simulations of human rhinovirus and an antiviral compound, BIOPHYS J, 80(1), 2001, pp. 121-129
Authors:
Brooks, BR
Sanjak, M
Belden, D
Waclawik, A
Citation: Br. Brooks et al., Motor neurone disease: Basic designs, sample sizes and pitfalls, CLINICAL TRIALS IN NEUROLOGY, 2001, pp. 427-450
Authors:
Brooks, BR
Miller, RG
Swash, M
Munsat, TL
Citation: Br. Brooks et al., El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis, AMYOTROPH L, 1(5), 2000, pp. 293-299
Authors:
Brooks, BR
Juhasz-Poscine, K
Waclawik, A
Sanjak, M
Belden, D
Roelke, K
Parnell, J
Weasler, C
Citation: Br. Brooks et al., Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: Beta-2 adrenergic agonists, AMYOTROPH L, 1, 2000, pp. 45-53
Authors:
Brooks, BR
Bushara, K
Khan, A
Hershberger, J
Wheat, JO
Belden, D
Henningsen, H
Citation: Br. Brooks et al., Functional magnetic resonance imaging (fMRI) clinical studies in ALS - paradigms, problems and promises, AMYOTROPH L, 1, 2000, pp. S23-S32
Authors:
Brooks, BR
Citation: Br. Brooks, Debating the possibility of earlier diagnosis of patients with amyotrophiclateral sclerosis, AMYOTROPH L, 1, 2000, pp. S1-S2
Authors:
Brooks, BR
Citation: Br. Brooks, Risk factors in the early diagnosis of ALS: North American epidemiologicalstudies, AMYOTROPH L, 1, 2000, pp. S19-S26
Authors:
Brooks, BR
Citation: Br. Brooks, Versailles minimal dataset for diagnosis of ALS: a distillate of the 2nd Consensus Conference on accelerating the diagnosis of ALS, AMYOTROPH L, 1, 2000, pp. S79-S81
Authors:
Johnson, KP
Brooks, BR
Ford, CC
Goodman, A
Guarnaccia, J
Lisak, RP
Myers, LW
Panitch, HS
Pruitt, A
Rose, JW
Kachuck, N
Wolinsky, JS
Citation: Kp. Johnson et al., Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years, MULT SCLER, 6(4), 2000, pp. 255-266
Authors:
Miller, RG
Anderson, FA
Bradley, WG
Brooks, BR
Mitsumoto, H
Munsat, TL
Ringel, SP
Citation: Rg. Miller et al., The ALS Patient Care Database - Goals, design, and early results, NEUROLOGY, 54(1), 2000, pp. 53-57
Authors:
Szurek, PF
Brooks, BR
Citation: Pf. Szurek et Br. Brooks, Synthesis of virus-specific high-mobility DNA after temperature upshift ofSC-1 cells chronically infected with moloney murine leukemia virus mutant ts1, J VIROLOGY, 74(15), 2000, pp. 7055-7063
Authors:
Zhou, J
Reich, S
Brooks, BR
Citation: J. Zhou et al., Elastic molecular dynamics with self-consistent flexible constraints, J CHEM PHYS, 112(18), 2000, pp. 7919-7929
Authors:
Venable, RM
Brooks, BR
Pastor, RW
Citation: Rm. Venable et al., Molecular dynamics simulations of gel (L-beta I) phase lipid bilayers in constant pressure and constant surface area ensembles, J CHEM PHYS, 112(10), 2000, pp. 4822-4832
Authors:
Waclawik, AJ
Vann, J
Schmelz, G
Szurek, P
Lewandoski, P
Brooks, BR
Citation: Aj. Waclawik et al., Zidovudine [AZT] myotoxicity: Quantitative separation of AZT effects on proliferation and differentiation of muscle cells in vitro. Lack of myotoxicity potentiation by retrovirus, NEUROTOXICO, 20(1), 1999, pp. 49-56
Authors:
Miller, RG
Rosenberg, JA
Gelinas, DF
Mitsumoto, H
Newman, D
Sufit, R
Borasio, GD
Bradley, WG
Bromberg, MB
Brooks, BR
Kasarskis, EJ
Munsat, TL
Oppenheimer, EA
Citation: Rg. Miller et al., Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review), MUSCLE NERV, 22(8), 1999, pp. 1104-1118
Authors:
Brooks, BR
Citation: Br. Brooks, Defining optimal management in ALS: from first symptoms to announcement - Introduction, NEUROLOGY, 53(8), 1999, pp. S1-S3
Authors:
Brooks, BR
Citation: Br. Brooks, What are the implications of early diagnosis? Maintaining optimal health as long as possible, NEUROLOGY, 53(8), 1999, pp. S43-S45
Authors:
Brooks, BR
Citation: Br. Brooks, Earlier is better: the benefits of early diagnosis, NEUROLOGY, 53(8), 1999, pp. S53-S54
Authors:
Brooks, BR
Citation: Br. Brooks, Closing remarks, NEUROLOGY, 53(8), 1999, pp. S72-S72
Authors:
Miller, RG
Rosenberg, JA
Gelinas, NF
Mitsumoto, H
Newman, D
Sufit, R
Borasio, GD
Bradley, WG
Bromberg, MB
Brooks, BR
Kasarskis, EJ
Munsat, TL
Oppenheimer, EA
Citation: Rg. Miller et al., Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology, NEUROLOGY, 52(7), 1999, pp. 1311-1323
Authors:
Kasarskis, EJ
Shefner, JM
Miller, R
Smith, RA
Licht, J
Mitsumoto, H
Hopkins, LC
Rosenfeld, J
Pascuzzi, R
Cornblath, DR
Armon, C
Strong, MJ
Kula, R
Windebank, A
Bosch, EP
Smith, BE
Cashman, N
Sivak, M
Sergay, S
Siddique, T
Sufit, RL
Johnston, W
Brooke, MB
Graves, MC
Olney, RK
Roos, RP
Neville, H
Ringel, SP
Ross, M
Bradley, WG
Sharma, KR
Parry, G
Mandler, R
Giuliani, M
Thornton, CA
Jackson, C
Bryan, W
Bromberg, M
Tandan, R
Fries, T
Phillips, L
Brooks, BR
Fenichel, G
Pestronk, A
Bear, M
Beatey, R
Fuller, C
Hill, R
Malta, E
Nakanishi, A
Patel, A
Thurmond, B
Cedarbaum, JM
Stambler, N
Citation: Ej. Kasarskis et al., A controlled trial of recombinant methionyl human BDNF in ALS, NEUROLOGY, 52(7), 1999, pp. 1427-1433
Authors:
Miller, RG
Munsat, TL
Swash, M
Brooks, BR
Citation: Rg. Miller et al., Consensus guidelines far the design and implementation of clinical trials in ALS, J NEUR SCI, 169(1-2), 1999, pp. 2-12
Authors:
Brooks, BR
Citation: Br. Brooks, Diagnostic dilemmas in amyotrophic lateral sclerosis, J NEUR SCI, 165, 1999, pp. S1-S9